Turnstone Biologics (NASDAQ:TSBX – Get Free Report) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Turnstone Biologics to post earnings of ($0.80) per share for the quarter.
Turnstone Biologics Stock Performance
Shares of Turnstone Biologics stock opened at $0.39 on Wednesday. The company’s fifty day simple moving average is $0.42 and its two-hundred day simple moving average is $0.49. The company has a market cap of $9.11 million, a P/E ratio of -0.12 and a beta of 2.04. Turnstone Biologics has a 12-month low of $0.34 and a 12-month high of $3.88.
Analysts Set New Price Targets
Separately, Piper Sandler downgraded shares of Turnstone Biologics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $3.75 to $0.40 in a research report on Wednesday, February 5th.
About Turnstone Biologics
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
See Also
- Five stocks we like better than Turnstone Biologics
- Stock Market Sectors: What Are They and How Many Are There?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Election Stocks: How Elections Affect the Stock Market
- 3 Must-Own Stocks to Build Wealth This Decade
- Financial Services Stocks Investing
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
